• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

    10/12/25 9:00:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLGN alert in real time by email

    Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases: Why is this pullback the golden moment CXC10 has been waiting for?

    The past 48 hours have been brutal for the entire crypto market. Amidst the market's turbulent volatility, approximately $16 billion in leveraged positions were forcibly liquidated, leaving many investors helpless to prevent a significant decline in their paper wealth.

    In times of widespread panic, we must remain calm. Declines often present opportunities. As Buffett famously said, "When others are greedy, I am fearful; when others are fearful, I am greedy."

    Let me share our perspective and plans for the future:

    1. Why the Decline: A Healthy, Inevitable "Stress Test"

    Over the past 48 hours, the crypto market has experienced an epic deleveraging event. Over $16 billion in positions (81% of which were long) were liquidated across the entire network within 24 hours, wiping out nearly $200 billion in total market capitalization.

    We believe this plunge is not a collapse of market fundamentals, but rather a "stress test" triggered by geopolitical factors, the macroeconomic environment, and internal structural leverage. The immediate trigger was geopolitical shocks: Trump's threat to impose 100% tariffs on China triggered risk aversion in global capital markets, with cryptocurrencies, as high-beta assets, bearing the brunt.

    The core issue was excessive leverage within the market. With liquidity drying up near the weekend and late in the Asian session, panic led to a cascade of liquidations, which is the primary cause of this pullback.

    Notably, Ethena's USDe revolving loan issue acted as a "risk amplifier" in this incident. While its brief unpegging only contributed approximately 10-15% of total liquidations, it exposed the vulnerability of some synthetic assets in the industry to extreme market conditions.

    Therefore, we believe this is not the beginning of a bear market, but rather an inevitable liquidation of unhealthy leverage and fragile structures within the industry, allowing true value to emerge.

    2. Turning Crisis into Opportunity: CXC10 (QLGN) Officially Launches Strategic Asset Purchases Starting Next Week

    For many, this is a fearful moment. But for CXC10, it is a moment of opportunity, one for which we are fully prepared. The greatest strength of a disciplined institutional investor is their ability to be fully prepared and remain greedy when others are panicking. We are delighted to see that many of the high-quality assets with excellent fundamentals that we have long focused on are entering our pre-defined, attractive value ranges. The course of time and the tide of history will not be altered by a single, non-systemic, random event. The trend of sustained growth in the value of leading crypto assets will continue. This is also the original intention of our C10 portfolio strategy.

    Over the past two weeks, we have successfully completed the establishment of infrastructure such as US dollar cash settlement, bank accounts, and cryptocurrency custody accounts. As of today, we have not purchased any virtual currencies. We hereby officially announce that the C10 Treasury, a subsidiary of CXC10 (QLGN), will officially begin purchasing its first batch of strategic assets starting next week.

    3. Our "Playbook": A Systematic SMART Investment Framework

    Our confidence stems not from gambled guesswork but from a systematic methodology that has been designed and stress-tested—our SMART Investment Framework. This framework is our guide for facing a downturn, particularly the R (Risk Management) module:

    Passive Defense: 80% of the C10 Treasury closely tracks the C10 Index, investing in the top 10 cryptocurrencies based on market capitalization. This has significantly impacted lower-ranked, smaller-cap cryptocurrencies much less than lower-ranked, smaller-cap cryptocurrencies during this epic correction.

    Active Allocation: 20% of the Treasury is allocated to the top 10 cryptocurrencies based on the team's rigorous quantitative analysis, with performance outperforming the index on average. For example, BNB, our largest allocation, has been one of the fastest-performing mainstream cryptocurrencies.

    Strategy Upgrade: Our 20% active allocation strategy will be further upgraded to include active hedging strategies including stablecoins, options, and structured products. These financial instruments have been built into our system from the outset, designed to effectively mitigate risks and protect our treasury's net value during extreme, one-way market fluctuations. Meanwhile, the S (Strategic Allocation) module within the framework has already laid out a clear asset allocation pyramid for us, giving us clear insights into what to buy. The M (Quantitatively Driven) module, through its scoring model, helps us accurately identify those fundamentally superior assets that have been "misprioritized" amidst the market's devastation.

    In the future, we will share our active allocation analysis and risk hedging strategies through blogs and other channels. Furthermore, we are actively promoting investment products such as C10 private funds and ETF public funds to expand our asset management scale and enable more investors who believe in cryptocurrency assets to achieve superior returns.

    4. Massive Attack: High-Quality Assets and Strategic M&A

    Our next investment and M&A focus will be on assets that were misprioritized during this recent market crash and that align with our long-term strategy:

    Core Blue-Chips: Core public chains with strong ecosystems and technological barriers, including Binance (BNB), Ethereum (ETH), and Solana (SOL).

    High-Growth Leaders: Leading projects in sectors such as AI, RWA, and oracles that have experienced significant corrections, whose long-term value remains unaffected by short-term panic. 

    Furthermore, the market correction presents us with a once-in-a-lifetime opportunity for industry expansion. In addition to purchasing assets in the secondary market, we will also leverage this market clearing to actively identify startups with excellent technology but limited cash flow for strategic mergers and acquisitions. This presents the perfect opportunity for us to rapidly expand our CXC10 industry footprint at the lowest cost. At the same time, we are also setting up our New York office, for people who are interested in joining us please contact [email protected].

    5. Long-Term Vision: The bull market logic remains unchanged, and we focus on the future.

    Finally, we must emphasize that short-term deleveraging events will not change our fundamental judgment on the long-term bull market in the crypto market. The underlying macroeconomic logic driving the dual bull market, driven by regulatory compliance, continued capital inflows from ETFs like Bitcoin, the Federal Reserve's interest rate cuts, and the technological revolution integrating AI and Web3, remains unwavering.

    Our mission is to build a Web3 ecosystem that is deeply integrated with the real economy and can weather both bull and bear markets. This healthy market correction has not shaken our confidence; instead, it has cleared the path for our departure and provided a perfect opportunity to embark.

    For CXC10 (QLGN), the real game is just beginning.

    About Qualigen Therapeutics, Inc.

    Qualigen Therapeutics, Inc. (NASDAQ:QLGN) is a biotechnology company headquartered in Carlsbad, California, focused on developing and commercializing innovative oncology and immunology therapeutics. The Company is actively pursuing crypto and web3 strategic initiatives that integrate advanced technologies and capital market innovation to accelerate global growth.

    Investor & Media Contact

    Investor Relations Department

    Qualigen Therapeutics, Inc.

    5857 Owens Avenue, Suite 300, Carlsbad, CA 92008

    Tel: +1 (760) 452-8111

    Email: [email protected]



    Primary Logo

    Get the next $QLGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QLGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLGN
    Leadership Updates

    Live Leadership Updates

    View All

    Qualigen Therapeutics, Inc. Announces management changes.

    CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. On September 25, 2024, the board of directors appointed Campbell Becher as President of the

    9/26/24 5:10:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

    CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division. "Shishir's consistent leadership as chief operating officer has been an essential part of our strategy to date. With the return of the sales and marketing of FastPack® last month, our diagnostics business is an essential asset to t

    4/29/22 9:15:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer

    New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer. Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy. "We are delighted to welcome Tariq to Qualigen as our Chief Medical Off

    5/19/21 7:30:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

    Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases: Why is this pullback the golden moment CXC10 has been waiting for? The past 48 hours have been brutal for the entire crypto market. Amidst the market's turbulent volatility, approximately $16 billion in leveraged positions were forcibly liquidated, leaving many investors helpless to prevent a significant decline in their paper wealth. In times of widespread panic, we must remain calm. Declines often present opportunities. As Buffett famously said, "When others are greedy, I am fearful; when othe

    10/12/25 9:00:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

    New York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $41 million strategic investment in its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen Therapertics"), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, from its client Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company. The total investment amounts to approximately $41 million

    9/30/25 4:00:00 PM ET
    $FFAI
    $QLGN
    Auto Manufacturing
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto

    Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or "the Company") today announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("FF"), along with its Founder and Global Co-CEO YT Jia, President Jerry Wang, SIGN Foundation – a blockchain technology company backed by Binance Labs, Sequoia Capital (US, India, China), IDG, and Circle, and other leading investors. FF has invested $30 million in QLGN common and preferred stock, representing approximately 55% of pro forma beneficial ownership. YT Jia, has personally invested approxim

    9/30/25 7:08:31 AM ET
    $FFAI
    $QLGN
    Auto Manufacturing
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    SEC Filings

    View All

    $QLGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form PRE 14A filed by Qualigen Therapeutics Inc.

    PRE 14A - Qualigen Therapeutics, Inc. (0001460702) (Filer)

    10/10/25 5:15:09 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Qualigen Therapeutics Inc.

    8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

    10/6/25 8:07:42 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

    10/3/25 5:27:31 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Bensler Graydon

    3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

    11/15/24 4:05:33 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Braeden Lichti

    3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

    10/17/24 4:05:15 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lim Robert Bradley

    3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

    8/9/24 4:01:09 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Qualigen Therapeutics Inc. (Amendment)

    SC 13G/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)

    5/27/22 9:22:10 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Qualigen Therapeutics, Inc.

    SC 13G - Qualigen Therapeutics, Inc. (0001460702) (Subject)

    12/6/21 5:04:28 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Financials

    Live finance-specific insights

    View All

    Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

    Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update: Highlights For Second Quarter and To Date 2023: Therapeutics Highlights: QN-

    8/15/23 8:30:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

    Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Therapeutics Highlights: QN-302 Orphan Drug Designation granted by FDA for the intended indication of pancreatic cancerGood laboratory practice (GLP) toxicology studies initiatedComposition

    5/16/23 8:00:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

    CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN, Inc.))), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company's therapeutics pipeline and other corporate developments. Highlights For 2022 and to Date: Therapeutics Highlights: QN-302 Secured worldwide rights to G4-selective transcription inhibitors from University College London to develop as cancer therapeuticsEngaged QN

    5/2/23 4:30:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care